Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 17/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 17/20 | 1.00 |
| ▸ | RELA | Q04206 | 17/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CLPX | O76031 | 1/20 | 0.81 |
| ▸ | VCP | P55072 | 1/20 | 0.81 |
| ▸ | RORA | P35398 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Withaferin A SCHEMBL12309163 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL30782710 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL12309137 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL20136632 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL17807718 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL24075907 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL11950371 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL157208 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| Withaferin A SCHEMBL18372363 | 1.00 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB | |
| SCHEMBL12309145 | 0.94 | NFKB1 (1.00) | NFKB1NFKB2RELANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4616854-A1 | TREATMENT OF MUSCLE SARCOPENIA | Molius Saglik Teknolojileri Anonim Sirketi (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4568688-A1 | WITHANIA SOMNIFERA COMPOSITION FOR COGNITIVE HEALTH | OmniActive Health Technologies Limited (IN) | 2025-06-18 | — | — | EP | claimed |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. | 2025-06-12 | — | — | US | claimed |
| WO-2025041168-A1 | WITHANIA SOMNIFERA COMPOSITION FOR COGNITIVE HEALTH | OMNIACTIVE HEALTH TECHNOLOGIES LIMITED (IN) | 2025-02-27 | — | — | WO | claimed |
| EP-4486348-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| EP-3585400-B1 | ANTI-PSYCHOTIC COMPOSITION AND TREATMENT METHODS | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2024-11-06 | — | — | EP | claimed |
| WO-2024199144-A1 | NOVEL REAGENT FOR MITIGATING LNP TOXICITY | SHANGHAI MOYIN THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | WO | claimed |
| US-12097236-B2 | Withania somnifera composition, method of preparation and use thereof | LAILA NUTRACEUTICALS (IN) | 2024-09-24 | — | — | US | claimed |
| WO-2024179699-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC. (US) | 2024-09-06 | — | — | WO | claimed |
| WO-2023166153-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC (US) | 2023-09-07 | — | — | WO | claimed |
| EP-4238564-A1 | NEW TREATMENTS OF RENAL CELL CARCINOMA | Bash Biotech Inc (US) | 2023-09-06 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20230226082-A1 | METHODS AND FORMULATIONS FOR TREATING AND PREVENTING LONG HAUL CORONAVIRUS (LONG COVID) SYMPTOMS AND SEQUELAE | Bioved Pharmaceuticals, Inc. (US) | 2023-07-20 | — | — | US | claimed |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-11 | — | — | US | claimed |
| US-20260130924-A1 | COMPOSITIONS AND METHODS OF TREATING SUBJECTS WITH BRCA1 MUTATION OR DEFICIENCY | UNIV TEXAS (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4676479-A1 | PARBENDAZOLE FOR USE IN THE TREATMENT OF DEMENTIA | Trustlife Global Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-11389472-B2 | Method of administration and treatment | DYVE BIOSCIENCES, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022040321-A1 | PROTECTION AGAINST CORONAVIRUS INFECTION BY EXTRACTS AND EXTRACT COMPONENTS | NATREON, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220054575-A1 | PROTECTION AGAINST CORONAVIRUS INFECTION BY EXTRACTS AND EXTRACT COMPONENTS | NATREON, INC. (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | RCC2, GLS, VHL | NFKB1 1386/4885NFKB2 1606/4885RELA 2190/4885 |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | GLA, LIMS1, GLB1 | NFKB1 852/4885NFKB2 1192/4885RELA 586/4885 |
| US-20260130924-A1 | COMPOSITIONS AND METHODS OF TREATING SUBJECTS WITH BRCA1 MUTATION OR DEFICIENCY | BRCA1, GPX4, GPX1 | NFKB1 1589/4885NFKB2 1580/4885RELA 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.